Abstract
A number of imaging modalities are showing promise as predictive and prognostic biomarkers in advanced renal cell carcinoma. This review discusses progress to date in this exciting area and identifies areas of future promise.
Highlights
Therapeutic options for patients with advanced renal cell carcinoma (RCC) have dramatically improved over the last few years with the advent of a number of novel agents targeting both tumour vasculature and tumour growth
This study showed that inhibition of tumour vascular permeability by sorafenib, demonstrated by a reduction in Ktrans, was associated with improved progression free survival (PFS) (p = 0.01)
A recent study by Powles and colleagues looked at the use of sequential FDG-positron emission tomography (PET) scanning as a correlative marker of overall survival (OS) in patients with RCC treated with sunitinib [Powles et al 2010]
Summary
Therapeutic options for patients with advanced renal cell carcinoma (RCC) have dramatically improved over the last few years with the advent of a number of novel agents targeting both tumour vasculature and tumour growth. No imaging modality has yet been validated that can predict the treatment response of RCC treated with targeted therapies. Imaging techniques that can assess vascularity and changes in vascularity of these tumours may have potential to be useful as predictive biomarkers.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
